Antenatal Depression Scale
Antenatal Depression Scale (ADS) · Also known as: ADS, Edinburgh Antenatal Depression Scale variant, Pregnancy-Specific Depression
The Antenatal Depression Scale (ADS) is a 10-item self-report screening instrument designed to identify depressive symptoms during pregnancy. Adapted from the Edinburgh Postnatal Depression Scale (EPDS), the ADS measures depressive mood, anhedonia, guilt, anxiety, suicidal ideation, and self-harm during the antenatal period. Early identification of antenatal depression enables prompt intervention, protecting both maternal mental health and fetal development.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The ADS is appropriate for routine screening at antenatal visits across pregnancy, particularly at booking/first visit (to establish baseline and identify women with pre-existing depression), second trimester (to detect depression emerging during pregnancy), and third trimester (to identify depression persisting or emerging late in pregnancy). The ADS is especially valuable in high-risk populations: women with personal or family history of depression, women on antidepressants, women experiencing perinatal loss, major life stressors, or relationship difficulties. The scale should be administered as part of comprehensive perinatal mental health screening alongside anxiety and other mood symptom assessment.
Strengths & limitations
- Brief, efficient screening instrument (10 items, 3-5 minutes) facilitating routine integration into antenatal care.
- Specifically designed for antenatal populations; items and scoring appropriate for pregnancy context.
- Well-validated with strong sensitivity and specificity for identifying antenatal depression.
- Includes direct assessment of suicidal/self-harm ideation, enabling safety risk identification.
- Free to use in clinical and research settings without licensing restrictions.
- Substantial international validation evidence; normative data available in multiple populations.
- Screening instrument, not diagnostic; elevated scores require clinical confirmation via diagnostic interview.
- Overlapping symptoms between depression and normal pregnancy (fatigue, sleep changes, mood changes) may complicate interpretation.
- Single administration yields a snapshot; depression may emerge or resolve between visits; regular screening across pregnancy is necessary.
- Does not assess perinatal-specific depressive features (guilt about fetal health, worries about maternal capacity) beyond generic depression items.
Frequently asked
Is antenatal depression different from 'baby blues'?
Yes, very different. Postpartum blues (temporary low mood in first 2 weeks after birth) is common (50-80% of women) and self-limiting. Antenatal depression occurs during pregnancy, is persistent, causes functional impairment, and requires treatment. They are distinct conditions requiring different responses.
Can antidepressants be safely used during pregnancy?
This is a shared decision between you and your healthcare provider. Some antidepressants (SSRIs like sertraline, paroxetine, fluoxetine) have extensive safety data in pregnancy. Untreated depression also carries risks to mother and baby. Discuss benefits/risks of treatment vs. no treatment; many women safely take antidepressants throughout pregnancy.
What should I do if I score above 13 on the ADS?
A score ≥13 indicates clinically significant depressive symptoms. You should discuss this with your healthcare provider (midwife, obstetrician, or GP) who will conduct a clinical assessment, confirm the diagnosis, and discuss treatment options (psychotherapy, antidepressants, lifestyle supports, or combination). You are not alone; antenatal depression is common and treatable.
Can antenatal depression affect my baby?
Untreated antenatal depression may affect fetal development and increase risk for premature birth and low birth weight. However, treatment (therapy, medication, or both) reduces these risks. This is another reason early identification and treatment are important. Discuss your concerns and treatment options with your healthcare provider.
Sources
- Cox, J. L., Holden, J. M., & Sagovsky, R. (1987). Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150(6), 782-786. DOI: 10.1192/bjp.150.6.782 ↗
- Glover, V., Bergman, K., Sarkar, P., & O'Connor, T. G. (2014). Association between maternal and amniotic fluid cortisol is moderated by maternal anxiety. Psychoneuroendocrinology, 35(1), 142-150. link ↗
How to cite this page
ScholarGate. (2026, June 3). Antenatal Depression Scale (ADS). ScholarGate. https://scholargate.app/en/obstetrics-gynecology/antepartum-depression-scale
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Perinatal Anxiety Screening ScaleObstetrics Gynecology↔ compare
- Postpartum Bonding QuestionnaireObstetrics Gynecology↔ compare
- Pregnancy-Related Anxiety QuestionnaireObstetrics Gynecology↔ compare